Premium
Genetic susceptibility to treatment response for FEP suggested
Publication year - 2019
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30372
Subject(s) - schizophrenia (object oriented programming) , antipsychotic , psychiatry , medicine , genome wide association study , psychosis , polygenic risk score , clinical psychology , single nucleotide polymorphism , genotype , gene , biology , genetics
Patients with higher polygenic risk scores (PRSs) for schizophrenia don't get as many benefits from antipsychotic medications as patients with lower risk scores, suggesting that PRSs may be useful as a biomarker for prognosis, researchers have found. In a study published in the January issue of the American Journal of Psychiatry , researchers examined whether PRSs based on genomewide association studies (GWASs) can quantify the influence of genes of a small effect in a single measure. Specifically, the authors looked at whether PRSs for schizophrenia predicted antipsychotic efficacy in four independent cohorts (total: 510 patients) with first‐episode psychosis (FEP).